Video Series: Current Topics in the Treatment of Advanced PCa
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.
Latest Prostate Cancer News
Smokeless tobacco "snus" users have high blood levels of nicotine which promotes cancer progression.
A PSA level of 1.5 ng/mL or higher should prompt primary care physicians to refer patients to a urologist for further evaluation.
The risk of dementia was 2-fold higher among ADT users.
A phase 3 study of ipilimumab among patients with metastatic, castration-resistant prostate cancer (mCRPC) did not meet its primary endpoint.
NEPC is an aggressive subtype of castration-resistant prostate cancer independent of androgen expression.
A body mass index of 30 kg/m2 or higher was was associated with 2-fold increased risk of dying from prostate cancer.
Researchers demonstrate a possible survival advantage by including cabazitaxel in sequences of new agents in the post-docetaxel setting.
Pooled analysis shows initial use of degarelix versus LHRH agonists was associated with improved PSA progression-free survival.
In a study, a drop in alkaline phosphatase level at 12 weeks compared with baseline was associated with a decreased risk of death and first symptomatic skeletal event.
In a PREVAIL trial post hoc analysis, nearly one fourth of men on enzalutamide had radiographic progression despite non-rising PSA.
After 20 years, the prostate cancer mortality rate was 0.7% for men with a PSA level of 10 ng/mL or less and benign initial biopsy results.
Metastasis-free survival correlates with overall survival in localized prostate cancer clinical trials.
Over a median follow-up of 70 months, 15% of men studied experienced biochemical recurrence.
Within each D'Amico risk category, African-American and Hispanic prostate cancer patients were less likely to receive definitive treatment than white patients.
Two new equations could better descriminate between clinical significant and indolent prostate cancer
Prostate Cancer Videos
Sign up for free e-Newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)